UNSPSC 51183507: Buformin hydrochloride

This classification denotes an anti-diabetic agent with the molecular formula C6H15N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D947SXO87P, chemically known as imidodicarbonimidic diamide, n-butyl- but more generally known as buformin hydrochloride, which bears US NIH Compound Identifier 2468. European Medicines Agency schedules Buformin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00892MIG.

Most nations, for tariff and trade purposes, schedule buformin hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, BUFORMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Buformin hydrochloride bears US NLM identifiers UMLS ID C2987056 and NCI Concept Code C95329. SMILES: CCCCNC(=N)NC(=N)N.CL.

UNSPSC 51183507 Buformin hydrochloride, a Commodity code, covers state and local procurement of this antidiabetic pharmaceutical ingredient supplied through authorized wholesaler distribution networks to health systems and state medicaid programs. State and local governments acquire buformin hydrochloride primarily as part of broader multi-source generic pharmaceutical contracts negotiated through cooperative purchasing alliances, where the drug is sourced alongside hundreds of other generic and over-the-counter products to supply hospital pharmacies, correctional health services, and public health departments. Issuing bodies under this code include state departments of administration and health, acting individually or through multistate cooperative purchasing consortia that aggregate demand across member states and municipalities to achieve volume discounts and standardized pricing terms.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026. Participating states include Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with awarded products effective July 1, 2026. Evaluation is weighted primarily on price competitiveness (75 percent), with secondary factors including fixed pricing structure (10 percent), EDI capability (5 percent), compliance with administrative data format requirements (5 percent), and acceptance of a 3 percent administrative fee (5 percent). Vendors must maintain current Good Manufacturing Practices certification, comply with the Drug Supply Chain Security Act, hold relationships with at least two of the three authorized wholesalers, and carry $5 million commercial general liability insurance and $2 million each in network security and professional liability coverage. Contract terms run two years for new responders with optional extensions, or align with existing expiration dates through June 30, 2028 for incumbent vendors.